These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33784603)

  • 1. Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms.
    Liu K; Zhao X; Qi X; Hou DL; Li HB; Gu YH; Xu QL
    Eur J Med Chem; 2021 Jun; 218():113388. PubMed ID: 33784603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of new 1,2,4-oxadiazole based trans- acrylic acid derivatives as potential PPAR-alpha/gamma dual agonist.
    Kaur P; Bhat ZR; Bhat S; Kumar R; Kumar R; Tikoo K; Gupta J; Khurana N; Kaur J; Khatik GL
    Bioorg Chem; 2020 Jul; 100():103867. PubMed ID: 32353564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats.
    Ge J; Miao JJ; Sun XY; Yu JY
    J Ethnopharmacol; 2016 Aug; 189():238-49. PubMed ID: 27224243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.
    Hanf R; Millatt LJ; Cariou B; Noel B; Rigou G; Delataille P; Daix V; Hum DW; Staels B
    Diab Vasc Dis Res; 2014 Nov; 11(6):440-7. PubMed ID: 25212694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent anti-diabetic effects of MHY908, a newly synthesized PPAR α/γ dual agonist in db/db mice.
    Park MH; Park JY; Lee HJ; Kim DH; Park D; Jeong HO; Park CH; Chun P; Moon HR; Chung HY
    PLoS One; 2013; 8(11):e78815. PubMed ID: 24244369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPAR dual agonists: are they opening Pandora's Box?
    Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
    Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.
    Ma Y; Wang SQ; Xu WR; Wang RL; Chou KC
    PLoS One; 2012; 7(6):e38546. PubMed ID: 22685582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-γ modulators.
    Naim MJ; Alam O; Alam MJ; Shaquiquzzaman M; Alam MM; Naidu VGM
    Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700223. PubMed ID: 29400412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
    Rudolph J; Chen L; Majumdar D; Bullock WH; Burns M; Claus T; Dela Cruz FE; Daly M; Ehrgott FJ; Johnson JS; Livingston JN; Schoenleber RW; Shapiro J; Yang L; Tsutsumi M; Ma X
    J Med Chem; 2007 Mar; 50(5):984-1000. PubMed ID: 17274610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
    Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
    Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy.
    Huang F; Zeng Z; Zhang W; Yan Z; Chen J; Yu L; Yang Q; Li Y; Yu H; Chen J; Wu C; Zhang XK; Su Y; Zhou H
    Eur J Med Chem; 2021 Oct; 222():113542. PubMed ID: 34118723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
    Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.
    Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L
    Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Design, synthesis, and PPARalpha/gamma agonistic activity of novel tetrahydroisoquinoline derivatives].
    Yu R; Zhou YL; Huan Y; Liu Q; Shen ZF; Liu ZZ
    Yao Xue Xue Bao; 2011 Mar; 46(3):311-6. PubMed ID: 21626786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
    Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
    Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
    Calkin AC; Giunti S; Jandeleit-Dahm KA; Allen TJ; Cooper ME; Thomas MC
    Nephrol Dial Transplant; 2006 Sep; 21(9):2399-405. PubMed ID: 16720596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.
    Xu Y; Etgen GJ; Broderick CL; Canada E; Gonzalez I; Lamar J; Montrose-Rafizadeh C; Oldham BA; Osborne JJ; Xie C; Shi Q; Winneroski LL; York J; Yumibe N; Zink R; Mantlo N
    J Med Chem; 2006 Sep; 49(19):5649-52. PubMed ID: 16970391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephroprotective effect of Combretum micranthum G. Don in nicotinamide-streptozotocin induced diabetic nephropathy in rats: In-vivo and in-silico experiments.
    Kpemissi M; Potârniche AV; Lawson-Evi P; Metowogo K; Melila M; Dramane P; Taulescu M; Chandramohan V; Suhas DS; Puneeth TA; S VK; Vlase L; Andrei S; Eklu-Gadegbeku K; Sevastre B; Veerapur VP
    J Ethnopharmacol; 2020 Oct; 261():113133. PubMed ID: 32673708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome.
    Li Z; Ren Q; Zhou Z; Cai Z; Wang B; Han J; Zhang L
    Eur J Med Chem; 2021 Dec; 225():113807. PubMed ID: 34455359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of novel dual PPARα/δ agonists for the treatment of T2DM.
    Ren Q; Deng L; Zhou Z; Wang X; Hu L; Xie R; Li Z
    Bioorg Chem; 2020 Aug; 101():103963. PubMed ID: 32480174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.